C. ELEGANS SCREEN FOR NOVEL ANTI-NEMATODE DRUGS

C. 新型抗线虫药物的线虫筛选

• 批准号: 6212203
• 负责人: ANN E SLUDER
• 金额: $ 9.61万
• 依托单位: CAMBRIA BIOSCIENCES, LLC
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-07-15 至 2001-01-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6212203
• 关键词: Caenorhabditis elegans; anthelmintics; drug screening /evaluation; genetic screening; high throughput technology; host organism interaction; phenotype; protein structure function

Over one billion people worldwide are affected by parasitic nematodes that cause various debilitating nutritional, gastrointestinal, and other diseases. Many such infections are not curable with existing medications and preventative vaccines are not yet feasible for these complex parasites. Our goal is to develop novel screens for safe anti-nematode compounds that will fulfill this human health need. Our approach is first to show that a key element of nematode Caenorhabditis elegans, and then to design high throughput compound screens that exploit the unique adaptability of C. elegans for miniaturized liquid-based handling This approach holds great promise for developing safe and selective anti-nematode drugs. PROPOSED COMMERCIAL APPLICATION: This Phase I plan will establish the foundation for using the model nematode C. elegans to study expression and secretion of proteins important in nematode parasitism. Our results will direct the Phase II develoment of high-throughput screens for compounds that block parasitism by inhibiting the function of these proteins. Such chemicals will be developed as anti-nematode drugs for unmet needs in human health. The screening technology pioneered here will also be applicable to chemical discovery programs that target other aspects of parasitic nematode biology.

全世界有超过10亿人受到寄生线虫的影响，寄生线虫导致各种衰弱， 营养、胃肠道和其他疾病。许多此类感染不是 用现有的药物和预防性疫苗治愈这些复杂的寄生虫尚不可行。我们的目标是开发新的筛选安全的抗线虫化合物，以满足人类健康的需求。我们的方法是首先证明线虫的一个关键元素 秀丽隐杆线虫，然后设计高通量的化合物筛选， C.独特的适应性elegans用于小型化的基于液体的处理 为开发安全和选择性的抗线虫药物提供了巨大的希望。 拟定商业应用： 该一期计划将为利用模式线虫C.优雅地 研究在线虫寄生中重要蛋白质的表达和分泌。我们的结果 将指导高通量筛选化合物的第二阶段开发， 通过抑制这些蛋白质的功能来抑制寄生。这些化学品将被开发为 抗线虫药物，以满足人类健康方面尚未满足的需求。筛选技术开创了 这里也将适用于针对其他方面的化学发现计划， 寄生线虫生物学